Rheumatoid Arthritis
Data from Protalex' Phase I clinical trial of PRTX-100 presented at pharmacology conference
Published in Medical Letter on the CDC and FDA, November 12th, 2006
The abstract was entitled: Phase I study of the safety and pharmacokinetics of staphylococcal protein A in healthy adults. PRTX-100 is in development for autoimmune disorders including rheumatoid arthritis and idiopathic thrombocytopenic purpura (ITP).
As previously announced, the data demonstrated that in a single dose Phase I clinical trial, PRTX 100 was safe and well tolerated. There were no serious adverse events deaths and no major safety lab or vital sign...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- HIV/AIDS Diagnostics
U.S. FDA approves test to help diagnose main virus that causes AIDS - HIV/AIDS Therapy
Tenofovir disoproxil fumarate partially protects against SIV infection - Influenza Prevention
Centers for Disease Control and Prevention awards $5.2 million to evaluate pandemic influenza - Influenza Vaccine
U.S. FDA approves additional vaccine for upcoming influenza season - Addiction Medicine
Hair analysis distinguishes internal drug incorporation from external contamination - Addiction Medicine
Prevalence of psychotic symptoms is increased among methamphetamine users - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
